News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
RIBO LIFE SCIENCE (06938.HK) Submits CTA to Europe for Core Product Vortosiran Targeting SPAF Indication
RIBO LIFE SCIENCE (06938.HK) announced that its core product Vortosiran (RBD4059) has successfully submitted a Phase 2b clinical trial application (CTA) to the European Medicines A...
Reset
Send
The window will close in 5 seconds
RIBO LIFE SCIENCE (06938.HK) Submits CTA to Europe for Core Product Vortosiran Targeting SPAF Indication
Close
Recommend
1
Positive
0
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

RIBO LIFE SCIENCE (06938.HK)  -2.250 (-3.475%)   announced that its core product Vortosiran (RBD4059) has successfully submitted a Phase 2b clinical trial application (CTA) to the European Medicines Agency (EMA) for stroke prevention in patients with atrial fibrillation (SPAF). This marks the worlds first small interfering RNA (siRNA) Factor XI (FXI) inhibitor in clinical trials for atrial fibrillation (AF), representing a significant milestone in the clinical development of siRNA therapeutics in the field of anticoagulation therapy.

The study forms part of the companys broader Phase 2b clinical program, which encompasses multiple planned studies targeting various thromboembolic cardiovascular indications.

Vortosiran is an siRNA therapeutic designed for the treatment of thrombotic diseases. It precisely and durably inhibits FXI, blocking the FXI-mediated coagulation pathway and thereby suppressing FXI coagulation activity. The therapy aims to deliver robust protection against thromboembolism while significantly reducing bleeding risk. Compared with existing anticoagulation treatments, it is expected to enhance patients clinical benefits while lowering bleeding risk. (jl/w)(HK stocks quote is delayed for at least 15 mins.)



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.